Health Condition 1: null- Abnormal Uterine Bleeding
Conditions
Interventions
Intervention1: IV iron carboxymaltose: Group 1 Will receive IV iron carboxymaltose. Maximal dose in a single day 15mg/kg, not to exceed 1000mg. Subsequent doses on day 7 and day 14. Drug diluted in 25
Sponsors
AIIMS Rishikesh
Eligibility
Inclusion criteria
Inclusion criteria: 1) Serum Hb >6g/dl and 2) Perimenopausal women in the age group of 40-51 years with anemia due to Heavy Menstrual Bleeding. 3) Not tolerating oral iron
Exclusion criteria
Exclusion criteria: 1) Age less than 40 years and more than 51 years 2) Anemia due to causes other than iron deficiency anemia 3) Chronic infections like hepatitis and HIV 4) Serum transaminase level greater than 1.5 times the upper limit of normal 5) Serum creatinine level of more than 2.0mg/dl 6) Patients with history of allergic reaction to intravenous iron infusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| â?¢ Rise in Hb levels / reticulocyte count above baseline, rate of rise in Hb in reference with timeTimepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| â?¢ Proportions of people acheieving normalisation of Hb (10.9g/dL) â?¢ Rise in serum ferritin and serum iron Timepoint: 3 months | — |
Countries
India
Contacts
Public ContactDr k Rupendra
Outcome results
None listed